Business
Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
Jaimy Lee·MarketWatch·November 17, 2026
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Read the full story at MarketWatch →